Invivyd, Inc. (IVVD)
| Market Cap | 424.21M +429.1% |
| Revenue (ttm) | 53.43M +110.5% |
| Net Income | -52.49M |
| EPS | -0.30 |
| Shares Out | 282.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,467,748 |
| Open | 1.430 |
| Previous Close | 1.430 |
| Day's Range | 1.430 - 1.530 |
| 52-Week Range | 0.483 - 3.070 |
| Beta | 0.71 |
| Analysts | Strong Buy |
| Price Target | 8.75 (+483.33%) |
| Earnings Date | May 14, 2026 |
About IVVD
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatmen... [Read more]
Financial Performance
In 2025, Invivyd's revenue was $53.43 million, an increase of 110.47% compared to the previous year's $25.38 million. Losses were -$52.49 million, -69.11% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for IVVD stock is "Strong Buy." The 12-month stock price target is $8.75, which is an increase of 483.33% from the latest price.
News
Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026
NEW HAVEN, Conn., May 07, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced th...
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on May 1, 2026, Invivyd granted 17 newly hired non-executive employees options to purchase an aggre...
Invivyd annouces Chairman Elia to speak at POLITICO Health Care Summit
Invivyd (IVVD) announced that Marc Elia, Chairman of the Invivyd Board of Directors, is a featured speaker at the POLITICO Health Care Summit on Tuesday, April 21. During the session,
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit
Elia to speak at the premier gathering of policy makers, industry leaders, and health experts between 11:30 AM ET – 12:00 PM ET on April 21 Event to be live streamed between 9:00 AM – 1:00 PM ET NEW H...
Invivyd provides update on Phase 3 DECLARATION study of VYD2311
Invivyd (IVVD) announced progress in its REVOLUTION clinical program for VYD2311, an investigational candidate for the prevention of symptomatic COVID-19. The company conducted a pre-specified sample ...
Invivyd announces discovery, advancement of measles antibody candidate VMS063
Invivyd (IVVD) announced the discovery and advancement of VMS063, a novel, potentially first- and best-in-class monoclonal antibody candidate for the treatment and prevention of measles. The company s...
Invivyd Transcript: Study update
VYD2311, a next-gen COVID-19 monoclonal antibody, is advancing in a pivotal study with expanded enrollment and strong FDA collaboration, while a novel measles antibody, VMS-063, shows high preclinical potency and targets unmet needs amid rising outbreaks. Both programs aim to complement or surpass vaccines for vulnerable populations.
Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles
NEW HAVEN, Conn., April 09, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced progress in its REVOLUTION clinical program for VYD2311, a novel monoclonal antibody investigational c...
Invivyd Announces Presentation at the World Vaccine Congress Washington
NEW HAVEN, Conn., March 30, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Robert Allen, Ph.D., Chief Scientific Officer at Invivyd, presented as part of the Antibodies for...
Invivyd Earnings Call Transcript: Q4 2025
REVOLUTION clinical program advanced with DECLARATION study reaching target enrollment and positive safety review. Q4 revenues grew 31% sequentially, and strong cash reserves support pivotal VYD2311 data in mid-2026. PEMGARDA adoption and pipeline expansion position the company for broader market impact.
Invivyd reports cash, cash equivalents of $226.7M as of December 31
Cash and cash equivalents were $226.7 million as of December 31, 2025. In the second half of 2025, Invivyd (IVVD) secured over $200 million of capital. Invivyd’s current cash and
Invivyd appoints Michael Mina as CMO
Invivyd (IVVD) announced the appointment of Michael Mina, M.D., Ph.D., as Chief Medical Officer. Mina is a former assistant professor at the Harvard T.H. Chan School of Public Health, Harvard
Invivyd reports FY25 EPS (30c) vs. ($1.43) last year
Reports revenue $53.4M, consensus $51.72M. “With potential commercialization of VYD2311 on the horizon, we are encouraged by continued commercial execution and appeal for monoclonal antibody prophylax...
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates
NEW HAVEN, Conn., March 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the fourth quarter and full year ended December 31, 2025, and recent business hi...
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer
NEW HAVEN, Conn., March 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the appointment of Michael Mina, M.D., Ph.D., as Chief Medical Officer.
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026
NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced ...
Invivyd announces peer-reviewed publication using CANOPY trial data
Invivyd (IVVD) announced a peer-reviewed publication by Invivyd that uses data from the recent CANOPY clinical trial of Invivyd’s monoclonal antibody pemivibart to predict clinical protection levels f...
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies
NEW HAVEN, Conn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced a peer-reviewed publication by Invivyd that uses data from the recent CANOPY pivotal clinical trial of ...
Invivyd management to meet virtually with BTIG
Virtual Meeting to be held on February 24 hosted by BTIG.
Invivyd aligns with FDA on LIBERTY Phase 3 trial of VYD2311
Invivyd (IVVD) received and is aligned with advice from the U.S. Food and Drug Administration on the LIBERTY Phase 3 clinical trial, which will assess the safety and immunologic profile
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
NEW HAVEN, Conn., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has received and is aligned with advice from the U.S. Food and Drug Administration (FDA) on the LIBE...
Invivyd announces partnership with ski champion Lindsey Vonn
Invivyd (IVVD) announced a partnership with ski champion Lindsey Vonn to elevate public understanding of antibodies, one of the most important parts of the immune system, and their role in
Invivyd, SPEAR Study Group plan to initiate Phase 2 trial of VYD2311
Invivyd (IVVD) and the SPEAR Study Group announced the plan to initiate a Phase 2 clinical trial evaluating monoclonal antibody VYD2311 in individuals with Long COVID or COVID vaccine injury.
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
NEW HAVEN, Conn., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) and the SPEAR Study Group today announced the plan to initiate a Phase 2 clinical trial evaluating monoclonal antibody ...
Invivyd reports preliminary Q4 PEMGARDA net product revenue of $17.2M
“We are pleased by strong top-line revenue growth of PEMGARDA(R) (pemivibart), which we believe is attributable to our commercial execution and the fundamental appeal of monoclonal antibody prophylaxi...